WO2009069546A1 - 代謝症候群の治療もしくは予防剤、検査方法、検査薬、及び代謝症候群の治療薬の候補化合物のスクリーニング方法 - Google Patents

代謝症候群の治療もしくは予防剤、検査方法、検査薬、及び代謝症候群の治療薬の候補化合物のスクリーニング方法 Download PDF

Info

Publication number
WO2009069546A1
WO2009069546A1 PCT/JP2008/071212 JP2008071212W WO2009069546A1 WO 2009069546 A1 WO2009069546 A1 WO 2009069546A1 JP 2008071212 W JP2008071212 W JP 2008071212W WO 2009069546 A1 WO2009069546 A1 WO 2009069546A1
Authority
WO
WIPO (PCT)
Prior art keywords
agent
metabolic syndrome
therapeutic
dna
nucleotide sequence
Prior art date
Application number
PCT/JP2008/071212
Other languages
English (en)
French (fr)
Inventor
Takayuki Shindo
Original Assignee
Japan Science And Technology Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Science And Technology Agency filed Critical Japan Science And Technology Agency
Priority to JP2009543774A priority Critical patent/JP5099856B2/ja
Priority to US12/734,864 priority patent/US8858915B2/en
Priority to EP08855467.0A priority patent/EP2221065B1/en
Priority to CN2008801174732A priority patent/CN101873866B/zh
Publication of WO2009069546A1 publication Critical patent/WO2009069546A1/ja

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knockout animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A01K2217/077—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out heterozygous knock out animals displaying phenotype
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A01K2217/206—Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Abstract

　本発明の課題は、生体内での安定性を向上できる代謝症候群の治療又は予防剤等を提供することである。 　代謝症候群の治療又は予防剤は、受容体活性改変タンパク質（ＲＡＭＰ）２をコードする以下の（ａ）から（ｄ）のいずれかに記載のＤＮＡ、又はこのＤＮＡがコードするポリペプチドを有効成分として含有する。 　（ａ）配列番号１記載の塩基配列を有するＤＮＡ 　（ｂ）配列番号１記載の塩基配列とストリンジェントな条件下でハイブリダイズできる塩基配列を有するＤＮＡ 　（ｃ）配列番号２記載のアミノ酸配列において１もしくは複数のアミノ酸が置換、欠失及び／又は付加されたアミノ酸配列をコードする塩基配列を有するＤＮＡ 　（ｄ）配列番号１記載の塩基配列と９０％以上の相同性を有する塩基配列からなるＤＮＡ
PCT/JP2008/071212 2007-11-26 2008-11-21 代謝症候群の治療もしくは予防剤、検査方法、検査薬、及び代謝症候群の治療薬の候補化合物のスクリーニング方法 WO2009069546A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2009543774A JP5099856B2 (ja) 2007-11-26 2008-11-21 代謝症候群の治療もしくは予防剤、検査方法、検査薬、及び代謝症候群の治療薬の候補化合物のスクリーニング方法
US12/734,864 US8858915B2 (en) 2007-11-26 2008-11-21 Therapeutic or prophylactic agent, detection method and detection agent for metabolic syndrome, and method for screening of candidate compound for therapeutic agent for metabolic syndrome
EP08855467.0A EP2221065B1 (en) 2007-11-26 2008-11-21 Therapeutic or prophylactic agent, detection method and detection agent for metabolic syndrome, and method for screening of candidate compound for therapeutic agent for metabolic syndrome
CN2008801174732A CN101873866B (zh) 2007-11-26 2008-11-21 代谢综合症的治疗或预防剂、检查方法、检查药、以及代谢综合症的治疗药的候选化合物的筛选方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007305122 2007-11-26
JP2007-305122 2007-11-26

Publications (1)

Publication Number Publication Date
WO2009069546A1 true WO2009069546A1 (ja) 2009-06-04

Family

ID=40678444

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/071212 WO2009069546A1 (ja) 2007-11-26 2008-11-21 代謝症候群の治療もしくは予防剤、検査方法、検査薬、及び代謝症候群の治療薬の候補化合物のスクリーニング方法

Country Status (5)

Country Link
US (1) US8858915B2 (ja)
EP (1) EP2221065B1 (ja)
JP (1) JP5099856B2 (ja)
CN (1) CN101873866B (ja)
WO (1) WO2009069546A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019054460A1 (ja) * 2017-09-13 2019-03-21 株式会社ジーンテクノサイエンス 抗ｒａｍｐ２抗体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01129599A (ja) 1987-11-13 1989-05-22 Matsushita Electric Ind Co Ltd スピーカシステム
JP2004057003A (ja) * 2002-06-03 2004-02-26 Norihiro Chano Ｒｂ１遺伝子誘導蛋白質（ｒｂ１ｃｃ１）及び遺伝子
WO2005110433A1 (ja) * 2004-05-17 2005-11-24 Kazuhiko Igarashi Bach2の発現が人為的に抑制されている非ヒト動物とその利用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4248853A (en) * 1978-09-08 1981-02-03 Solomon Halbert Snyder Assay method and kit
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
WO1999009155A1 (en) * 1997-08-19 1999-02-25 Human Genome Sciences, Inc. 70 human secreted proteins
SE9702457D0 (sv) * 1997-06-26 1997-06-26 Pharmacia & Upjohn Ab Screening
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
WO2004050834A2 (en) * 2002-11-27 2004-06-17 Genpath Pharmaceuticals, Incorporated GPC99 AND GPC99a: METHODS AND COMPOSITIONS FOR TREATING CANCER
WO2006042242A2 (en) * 2004-10-08 2006-04-20 Amylin Pharmaceuticals, Inc. Amylin family polypeptide- 6 (afp- 6) analogs and methods of making and using them
GB0521139D0 (en) * 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01129599A (ja) 1987-11-13 1989-05-22 Matsushita Electric Ind Co Ltd スピーカシステム
JP2004057003A (ja) * 2002-06-03 2004-02-26 Norihiro Chano Ｒｂ１遺伝子誘導蛋白質（ｒｂ１ｃｃ１）及び遺伝子
WO2005110433A1 (ja) * 2004-05-17 2005-11-24 Kazuhiko Igarashi Bach2の発現が人為的に抑制されている非ヒト動物とその利用

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
FUKAI, N. ET AL.: "Concomitant expression of adrenomedullin and its receptor components in rat adipose tissues", AM J PHYSIOL ENDOCRINOL METAB, vol. 288, no. 1, 2005, pages E56 - E62 *
J. KATO ET AL., HYPERTENS. RES., 2002
P. NIU; T. SHINDO ET AL., CIRCULATION, 2004
See also references of EP2221065A4 *
T. NAMBU ET AL., REGUL PEPT., 2005
T. SHINDO ET AL., CIRCULATION, 2000
T. SHINDO ET AL., CIRCULATION, 2001
TAM, C.W. ET AL.: "Effect of L-NAME on blood pressure regulation in mice overexpressing the adrenomedullin receptor component RAMP2", ACTA PHARMACOLOGICA SINICA, vol. 27, no. SUPPL, 2006, pages 146 - 147 *
TAM, C.W. ET AL.: "Enhanced vascular responses to adrenomedullin in mice overexpressing receptor activity-modifying protein 2", CIRC RES, vol. 98, no. 2, 2006, pages 262 - 270 *
Y. IMAI; T. SINDO ET AL., ATVB, 2002

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019054460A1 (ja) * 2017-09-13 2019-03-21 株式会社ジーンテクノサイエンス 抗ｒａｍｐ２抗体

Also Published As

Publication number Publication date
US8858915B2 (en) 2014-10-14
EP2221065A4 (en) 2011-05-11
CN101873866B (zh) 2013-10-16
EP2221065B1 (en) 2016-12-28
CN101873866A (zh) 2010-10-27
US20110027187A1 (en) 2011-02-03
EP2221065A1 (en) 2010-08-25
JP5099856B2 (ja) 2012-12-19
JPWO2009069546A1 (ja) 2011-04-14

Similar Documents

Publication Publication Date Title
MX348464B (es) Agente inductor de inmunidad.
NZ604818A (en) Variants of activin iib receptor polypeptides and uses thereof
NZ602170A (en) Modified leptin polypeptides and their uses
EP2261249A3 (en) KDR peptides and vaccines comprising the same
WO2007076162A3 (en) Antimicrobial cathelicidin peptides
NZ606427A (en) Extended recombinant polypeptides and compositions comprising same
WO2010135491A3 (en) Fibroblast growth factor mutants having improved functional half-life and methods of their use
NZ593893A (en) Gene encoding human glucokinase mutant, enzyme encoded by the same, recombinant vectors and hosts, pharmaceutical compositions and uses thereof, methods for treating and preventing diseases
WO2009069808A1 (ja) 新規活性を有するEphA4ポリペプチドおよびその用途
HK1089788A1 (en) A recombinant protein with cancer suppression action, its encoding gene and use
WO2007029262A3 (en) Compositions and methods using same for the detection of viruses
WO2006116763A3 (en) Lawsonia intracellularis immunological proteins
WO2008047370A3 (en) Compositions and methods for inducing angiogenesis
WO2008049098A3 (en) ANTIBODY ANTAGONISTS OF INTERLEUKIN-13 RECEPTOR α1
WO2006097432A3 (de) Keratin-biktdende desmoplakinpolypeptidsequenzen
WO2010026219A3 (en) New tomato ethylene response factors and uses thereof
EP1842911A4 (en) HLA BINDING PEPTIDES, FOR THOSE CODING DNA FRAGMENTS AND RECOMBINANT VECTORS
WO2005072766A3 (en) Peptides that bind to hsp90 proteins
WO2009069546A1 (ja) 代謝症候群の治療もしくは予防剤、検査方法、検査薬、及び代謝症候群の治療薬の候補化合物のスクリーニング方法
WO2010103515A3 (en) Compositions and methods for prevention and treatment of neurodegenerative diseases
WO2008112543A3 (en) Rat, rabbit, and cynomolgus monkey il-21 and il-22 nucleotide and polypeptide sequences
EP1757687A4 (en) HLA BINDING PEPTIDE, PRE-STEP, DNA DOMAGING AND RECOMBINANT VECTOR
EP1801211A4 (en) BINDING PEPTIDE HLA MOLECULE, DNA FRAGMENT ENCODING SAME, AND RECOMBINANT VECTOR
WO2006010805A3 (fr) Nouveaux polypeptides pour la mise en evidence in vitro et la prevention des infections a legionella pneumophila
WO2005086595A3 (ja) テロメアタンパク質ｔｒｆ２ｄｎａ結合ドメイン変異体タンパク質、テロメアｄｎａ変異体及びｔｒｆ２ｄｎａ結合ドメインと二重らせんｄｎａとの複合体構造の利用

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880117473.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08855467

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2009543774

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12734864

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2008855467

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008855467

Country of ref document: EP